- Home
- CELU vs PASG Comparison
CELU vs PASG Comparison
Compare CELU & PASG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CELU | PASG |
|---|---|---|
| Founded | 2016 | 2017 |
| Country | United States | United States |
| Employees | N/A | 27 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.3M | 14.6M |
| IPO Year | 2019 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CELU | PASG |
|---|---|---|
| Price | $1.00 | $3.38 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $15.50 |
| AVG Volume (30 Days) | ★ 114.6K | 15.5K |
| Earning Date | 11-13-2026 | 11-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $26,550,000.00 | N/A |
| Revenue This Year | $165.42 | N/A |
| Revenue Next Year | $305.36 | N/A |
| P/E Ratio | $26.13 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $3.29 |
| 52 Week High | $2.55 | $20.00 |
Technical Indicators
Market Signals| Indicator | CELU | PASG |
|---|---|---|
| Relative Strength Index (RSI) | 35.76 | 34.64 |
| Support Level | $0.63 | $3.29 |
| Resistance Level | $1.43 | $4.92 |
| Average True Range (ATR) | 0.14 | 0.36 |
| MACD | -0.06 | -0.03 |
| Stochastic Oscillator | 5.73 | 1.93 |
Price Performance
Historical ComparisonAbout CELU Celularity Inc.
Celularity Inc is a regenerative and cellular medicine company focused on developing placental-derived allogeneic cell therapies and biomaterial products for the treatment of degenerative diseases, aging-related conditions, cancer, and immune disorders. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. It generates the majority of its revenue from the Degenerative Disease segment.
About PASG Passage Bio Inc.
Passage Bio Inc is a clinical-stage genetic medicines company focused on improving the lives of patients with neurodegenerative diseases. Their primary focus is the development and advancement of cutting-edge, one-time gene therapies designed to target critical underlying pathologies in these conditions. The Company operates in a single reportable segment, developing and advancing genetic medicines designed to target the critical underlying pathology of neurodegenerative diseases. The pipeline having PBFT02.